|Bid||30.740 x 150000|
|Ask||30.780 x 150000|
|Day's Range||30.706 - 30.817|
|52 Week Range||27.165 - 33.050|
|PE Ratio (TTM)||19.01|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Roche recently sued Pfizer to block the latter’s biosimilar (generic version) for Herceptin- a cancer biologic that earned $2.5 billion in sales in the U.S. for Roche in 2016. The fight is unlikely to stop there for Roche, as it has a lot more at stake.
Spark Therapeutics shares have plunged today, falling $27, or 37%, to $44.03 after the gene-therapy company released disappointing results for its treatment for hemophilia A at the American Society of Hematology’s annual meeting in Atlanta. The data on four patients in a phase 1/2 clinical trial showed some variability in the expression of Factor VIII, the clotting protein either missing or existing at very low levels in hemophilia A patients. It appears that Spark (ONCE) has lost the lead in developing a hemophilia A treatment to BioMarin Pharmaceutical (BMRN), a much larger biotechnology company that reported consistent levels of Factor VIII expression at the ASH conference in a phase 1/2 trial for its gene-therapy treatment.
Blueprint unveiled new data from its ongoing Phase 1 study of avapritinib in advanced systemic mastocytosis at the 59th American Society of Hematology Annual Meeting.
Shares of Teva Pharmaceutical Industries Ltd. rose 0.4% in morning trade Monday, after the drug maker announced the exclusive launch of its generic Viagra tablets in the U.S. The company said it will offer ...
Data include eleventh participant in the trial. Annualized bleeding rate for all 11 participants was reduced by 97 percent, while a nnualized infusion rate was reduced 99 percent as of Nov. 29, 2017 data ...
Patients with advanced breast cancer tied to an inherited gene mutation who were treated with an experimental Pfizer Inc drug went about three months longer before their disease worsened than those who received chemotherapy in a late stage study, according to data released on Friday. The drug, talazoparib, a once daily pill that Pfizer acquired with its $14 billion purchase of Medivation, belongs to a class of medicines called PARP inhibitors that may induce tumor cell death. Patients in the Phase III study had mutations of the BRCA1/2 genes, the type of mutation that led actress Angelina Jolie to have preventive breast removal surgery.
Pfizer Inc. today announced that the Phase 3 EMBRACA trial in patients with germline BRCA1/2-positive locally advanced and/or metastatic breast cancer demonstrated superior progression-free survival in patients treated with talazoparib, compared to patients who received physician’s choice standard of care chemotherapy.
In 3Q17, Eli Lilly’s (LLY) Humalog generated revenues of $696.2 million, ~9% growth on year-over-year (or YoY) basis and 3% growth on a quarter-over-quarter basis.
Allergan reported EPS of $4.15 on revenues of $4.03 billion in 3Q17, which was 11.4% higher YoY, compared with its revenues of $3.62 billion in 3Q16.
The promise of gene therapy to cure genetic diseases is underscored by a new article in The New England Journal of Medicine about a treatment for hemophilia B being developed by Spark Therapeutics (ONCE) and Pfizer (PFE). Spark and Pfizer have highlighted the article, which was based on previously reported data on 10 men who received the treatment and who were followed for about a year. The gene therapy uses a delivery system of neutered viruses to introduce healthy genes that code for the production of the clotting factor protein into the cells of patients with hemophilia B. A faulty gene caused by an inherited mutation prevents the production of that factor in hemophilia patients.
Rating Action: Moody's assigns A1 to Pfizer's new sterling notes; stable outlook. Global Credit Research- 07 Dec 2017. © 2017 Moody’ s Corporation, Moody’ s Investors Service, Inc., Moody’ s Analytics, ...
Pfizer Inc. today announced that it has commenced a private offer to exchange any and all of its outstanding £1,500,000,000 6.500 per cent.
The little blue pill that's helped millions of men in the bedroom is turning white. Drugmaker Pfizer is launching its own cheaper generic version of Viagra rather than lose most sales when the impotence ...
Spark Therapeutics Inc. stock surged Wednesday afternoon after the company announced positive results from a study of a gene-therapy approach to hemophilia. The drug, developed and tested in a collaboration ...
PHILADELPHIA and NEW YORK, Dec. 06, 2017-- Spark Therapeutics, a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, and Pfizer Inc., today announced that ...
Pfizer Inc. today announced updated progression-free survival results from the Phase 3 PALOMA-2 trial reinforcing the clinical benefit of IBRANCE® combined with letrozole.
When AstraZeneca Plc paid $2.7 billion for an experimental drugmaker in 2015, it had its sights set on a potential blockbuster medicine. Instead, it got a Texas factory riddled with defects and two scathing ...